Agenus Appoints New Director and Plans Equity Offering
PremiumCompany AnnouncementsAgenus Appoints New Director and Plans Equity Offering
3M ago
Agenus reports Q2 EPS ($2.52)  vs. ($3.93) last year
Premium
The Fly
Agenus reports Q2 EPS ($2.52) vs. ($3.93) last year
3M ago
Agenus publishes study on Botensilimab’s activity in treatment-resistant cancers
Premium
The Fly
Agenus publishes study on Botensilimab’s activity in treatment-resistant cancers
3M ago
Agenus downgraded to Market Perform from Outperform at William Blair
PremiumThe FlyAgenus downgraded to Market Perform from Outperform at William Blair
4M ago
H.C. Wainwright downgrades Agenus after FDA denies accelerated approval
Premium
The Fly
H.C. Wainwright downgrades Agenus after FDA denies accelerated approval
4M ago
Agenus downgraded to Neutral from Buy at H.C. Wainwright
Premium
The Fly
Agenus downgraded to Neutral from Buy at H.C. Wainwright
4M ago
FDA  grants Agenus meeting to discuss BOT/BAL Therapy for r/r MSS mCRC
PremiumThe FlyFDA grants Agenus meeting to discuss BOT/BAL Therapy for r/r MSS mCRC
6M ago
Ligand Pharmaceuticals, Agenus in $100M royalty financing agreement
Premium
The Fly
Ligand Pharmaceuticals, Agenus in $100M royalty financing agreement
6M ago
Agenus reports Q1 EPS ($3.04), consensus ($2.83)
Premium
The Fly
Agenus reports Q1 EPS ($3.04), consensus ($2.83)
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100